Live

LabiotechEpisode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech media Lonza NewsLonza and Stipple Bio partner to advance next-generation precision oncology ADC therapies - Indian Pharma Post Eli LillyGilead, Merck, Eli Lilly lead $106B biopharma takeover wave in 2026 - MSN Thermo FisherThe Bull Case For Thermo Fisher Scientific (TMO) Could Change Following AI-Enhanced Orbitrap Drug Discovery Launches – Learn Why - Yahoo Finance Bio-Gene Technology LtdBio-Gene lifts placement size with additional shares and options - TipRanks 10x Genomics BlogThis $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116% - AOL.com Eli LillyGilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026 - Stocktwits PfizerPfizer gets a jump on Chai's new model, thanks to drug discovery pact - FirstWord Pharma Endpoints NewsOtsuka touts new IgAN evidence as it seeks full approval for Voyxact AgilentA Look At Agilent Technologies (A) Valuation As FDA Approval AI Deal And Earnings Update Draw Focus - simplywall.st Boston ScientificBoston Scientific to open $138M medical device distribution facility in Indiana, adding 300 jobs - MassDevice Charles RiverCharles River Laboratories stock (US1591881009): Insider grant and fresh fund buying keep focus on C - AD HOC NEWS

PharmaVoice Nov 21, 2025

Pharma faces a critical ‘turning point’ in 2026, years in the making

While Trump’s manufacturing and pricing deals with pharma shape the industry’s future, COVID’s impact still ripples throughout the health landscape.

While Trump’s manufacturing and pricing deals with pharma shape the industry’s future, COVID’s impact still ripples throughout the health landscape.